TNFRSF9 and neoplasm: This was initially reported for agonistic anti-DR5 antibodies that require cross-linking by FcγRIIB in order to successfully elicit tumor control but has now been shown for multiple tumor necrosis factor receptor super-family (TNFRSF) members such as CD40, 4-1BB and OX40, at least in pre-clinical models [109,110,111,112,113,114].